Pfizer Announces Positive Topline Results From Phase 3 Study of Hemophilia A Gene Therapy Candidate Giroctocogene Fitelparvovec

July 24, 2024

Pfizer announces positive Phase 3 results for hemophilia A gene therapy candidate giroctocogene fitelparvovec, showing significant reduction in annualized bleeding rate post-infusion and generally well-tolerated profile.

Related Clinical Trials

Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults

A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)

Highlighted Terms

EMA’s Committee for Medicinal Products for Human Use BEQVEZ™marstacimab University of California NCT03587116 European Commission giroctocogene fitelparvovec U.S. Food and Drug Administration (FDA)hemophilia A fidanocogene elaparvovec NCT04370054 Sangamo Therapeutics Pfizer Inc.

Related News

Pfizer Announces Positive Topline Results From Phase 3 Study of Hemophilia A Gene Therapy Candidate Giroctocogene Fitelparvovec

Pfizer announces positive Phase 3 results for hemophilia A gene therapy candidate giroctocogene fitelparvovec, showing significant reduction in annualized bleeding rate post-infusion and generally well-tolerated profile.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy